2 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow CTNNB1 Foundation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome Urbagen gene addition therapy, Sirolimus, Methylprednisolone (Corticosteroid) - CTNNB1 Neurodevelopmental Syndrome | Phase 1 / Phase 2 | Recruiting | CTNNB1 Foundation | 12 | 2025-11-01 | 2026-03-25 |
| CTNNB1 Neurodevelopmental Syndrome - Natural History Study A General Medical and Neurological Assessment, World Health Organisation (WHO) Motor Milestones, Burke-Fahn-Marsden Dystonia Rating Scale - CTNNB1 Neurodevelopmental Syndrome | Recruiting | University Medical Centre Ljubljana | 250 | 2024-06-14 | 2025-09-22 |
Autism Spectrum Disorder (1) · Learning Disabilities (1)
Adrenal Cortex Hormones (1) · Methylprednisolone (1) · Neurologic Examination (1) · Sirolimus (1) · Tomography, Optical Coherence (1)
Slovenia (2) · Australia (1)
2025 (1)